Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, has entered into an Associate Partnership agreement with Charlotte FC to raise awareness of its flagship brands, including AI Tape and AVERSA. The company plans to leverage the partnership to enhance exposure for AI Tape, which is manufactured in the Charlotte region through its Pocono Pharmaceutical subsidiary. Nutriband also aims to spotlight its AVERSA platform, touted as a potential first-in-class abuse-deterrent patch for chronic pain management.
Sunshine Biopharma (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, has closed its previously announced registered direct offering with institutional investors of approximately $2.46 million shares of common stock and pre-funded warrants at a price of $2.07 per share of common stock. The company received aggregate gross proceeds of approximately $2.46 million from the offering, of which it intends to use the net for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as counsel to the company, and Kaufman & Canoles, P.C. acted as counsel to Aegis.
ADHD, or attention deficit hyperactivity disorder, is usually diagnosed during one’s childhood, but more adults are being diagnosed with this condition. Experts have observed that among adults diagnosed with ADHD, the likelihood of developing dementia is heightened, but it hasn’t been clear why this is the case. Now a new study suggests a possible explanation for the increased possibility of dementia development among adult ADHD sufferers.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate, HyBryte(TM) (“SGX301”), has already demonstrated positive results in a prior phase 3 trial, and Soligenix is now conducting a phase 3 replication study to further validate its efficacy and safety ( https://ibn.fm/zdRnQ ). This development marks an important milestone in the company’s mission to address an urgent medical need in a condition with limited treatment options.
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), will participate in the upcoming Jones Las Vegas Technology and Innovation Conference at The Venetian Resort. The April 8-9 event, organized by JonesTrading and supported by B2i Digital, provides a platform for direct engagement between innovative companies and institutional investors ( https://ibn.fm/fIKDc ).
Fifty 1 Labs (OTC: FITY), a forward-thinking leader in biotechnology and health innovation, today announced a groundbreaking achievement by its recently acquired subsidiary, Genetic Networks, in space-based biotechnology. The milestone stems from over a decade of space-based functional genomics from Dr. Corey Nislow’s laboratory, with the work highlighting the pivotal role of functional genomics in diverse aspects of human health and wellness. According to Dr. Nislow, the experiment findings have the potential to unlock new pathways for pharmaceutical development and human health in space exploration.
Cutaneous melanoma is the most aggressive skin cancer type and it is characterized by manifesting diverse mutations. Under normal circumstances, several of these mutations could be identified as threats by the immune system, but in this type of cancer, this doesn’t happen . Consequently, most patients are unresponsive to immunotherapy. This challenge has baffled oncology researchers for years.
Although companies such as Tesla, Rivian and legacy automakers such as Ford and GM have dominated headlines this year, these lesser known brands captivated Stocktwits users more in Q1 2025.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced completion of the safety lead-in for its Phase 2 trial evaluating ENV105 in combination with apalutamide for metastatic, castration-resistant prostate cancer. The trial will now proceed with patient randomization to assess apalutamide alone versus the combination therapy. Safety and efficacy data from the lead-in phase are expected in the first half of 2025. The company is also validating biomarkers to identify patients most likely to benefit from ENV105 and continues enrollment at cancer centers in Los Angeles and Salt Lake City.
A recently published report indicates that the rate at which Medicare Advantage plans are growing is slowing down. The report was authored by HealthScape Advisors, a consulting company, together with Chartis, a healthcare advisory company.
Recent vehicle sales data from Europe reveals that Tesla, historically the world’s largest electric vehicle (EV) manufacturer, is losing ground to established automakers like Volkswagen and BMW Group. According to research platform JATO Dynamics, both BMW and Volkswagen sold more EVs than Tesla in the European market in February 2025, signaling trouble for the Texas-based automaker.
BMW has officially put the brakes on its plans to switch to solid-state batteries, citing high costs as the primary reason. While many automakers are racing to adopt this next-generation battery technology, BMW is taking a different approach. Instead of transitioning to solid-state batteries right away, the German carmaker is doubling down on improving lithium-ion batteries, which they believe still have untapped potential.
Alibaba launched a new AI model Qwen2.5-Omni-7B that can process multiple inputs and generate real-time responses. It's open-sourced and can be deployed on edge devices. It's part of China's AI boom, with Alibaba investing heavily in cloud and AI infrastructure.
Paradise Car Keys sets the standard for mobile car locksmith services in the Gold Coast, delivering fast, reliable solutions for all vehicle brands, with specialized expertise in luxury models like BMW, Mercedes, Land Rover, and Porsche. Equipped with cutting-edge technology, the team offers key cutting, programming, ignition repairs, and transponder key services with unmatched precision.
The automotive industry stands at a pivotal juncture in 2025, poised for transformative changes driven by technological innovation, environmental pressures, shifting consumer preferences, and evolving regulatory landscapes. Over the next decade, as with any other decade in the past 100 years, we can expect seismic shifts that will redefine how
Boris Mizhen has been championing the benefits of big data for some time. If more established brands successfully implement a more personalized experience alongside their aptitude for data management and analysis, impersonal advertising will be over.
Glioblastoma continues to be one of the most challenging cancers to treat as it resists even the latest innovations in immunotherapy. Now, a new study conducted by a team at the Sylvester Comprehensive Cancer Center at the University of Miami suggests that, when a specific protein is suppressed, an antiviral immune response increases the effectiveness of immune checkpoint inhibitors .
Not Your Basic Locksmith continues to set the benchmark for automotive locksmith in Arlington TX, and the wider DFW area. Specializing in both domestic and foreign vehicles, the company offers a wide array of solutions, including Mercedes car key replacement , ignition repair, smart key duplication, and fob programming, all delivered with precision and professionalism.
New research that appeared in the journal Oncotarget has opened the door to a new way to approach the treatment of oral ulcers induced by chemotherapy. This debilitating and painful side effect of cancer treatment lowers the quality of life of patients undergoing chemotherapy, but oral mucositis remains an unmet medical need.
Tesla, once the leader in the electric vehicle (EV) industry, is now struggling with falling sales . The situation has led to competitors like BMW to grow their share in the EV market. With a strong lineup of battery-electric vehicles (BEVs), new technology, and a strategy that includes different types of vehicles, BMW is positioning itself as a major player in the EV industry.
